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Summary: We describe an interesting and novel alternative to conventional irrtmunoassay techniques for the measure-
ment of antigens and antibodies in body fluids. 
The label used for all assays is a pyruvate kinase-IgG conjugate of the relevant second (species-specific) antibody. All 
assays follow the same principle in which a solid phase antigen is used to adsorb unreacted first (substance-specific) 
antibody following a conventional antibody-antigen reaction in a liquid phase. After washing, the solid phase antigen-
first antibody is allowed to react with the labelled second antibody. The solid phase is then washed and the pyruvate 
kinase bound to the solid phase is used to generate ATP which is measured kinetically in a luminometer. 
Assays are described for insulin, insulin antibodies and gentamicin to demonstrate both the versatility and sensitivity 
of this type of assay. 
The insulin assay had a lower detection limit of under 0.25 /iU per tube and was comparable with the radioimmuno-
assay used for routine purposes both in sensitivity and reproducibility. The insulin antibody assay correlated well with 
the radiometric determination used routinely in the laboratory. 
The gentamicin assay correlated well with the routine commercial radioimmunoassay and also had comparable co-
efficients of variation. 
In all cases, the inter- and intra-assay variation was under 10% in the range of interest. 
Solid Phase Antigen Lumineszenz immunoassays (SPALT) für die Bestimmung von Insulin, Insulin-Antikörper und 
Gentamicin im menschlichen Serum 
Zusammenfassung: Es wird eine Alternative zu der herkömmlichen Immunoassay-Technik für die Bestimmung von 
Antigenen und Antikörpern in biologischen Flüssigkeiten beschrieben. 
Allen Assays liegt das gleiche Prinzip zugrunde, wonach zunächst eine Antigen-Antikörper-Reaktion abläuft. Durch 
nachfolgende Zugabe des gleichen, jedoch an einen festen Träger gebundenen Antigens werden die noch freien Anti-
körper abgefangen. Diese „ersten" Antikörper stellen das Antigen eines „zweiten" Antikörpers (Pyruvatkinase-IgG-
Konjugat) dar: hiermit ist es möglich, eine dem „ersten" Antikörper entsprechende Menge Pyruvatkinase an das 
Trägermaterial zu binden. 
0340-076X/82/0020-0825S02.00 
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In dem anschließenden Bestimmungsansatz bildet dieses Enzym ATP, dessen Synthese-Kinetik in einem Luminometer 
gemessen wird. An den Beispielen der Insulin-, Insulin-Antikörper- und Gentamicinbestimmungen wird die Empfindlich-
keit und die Vielseitigkeit dieser Methode demonstriert. 
Bei der Insulinbestimmung liegt die Nachweisgrenze unter 0,25 fi\J im Ansatz und ist somit vergleichbar mit dem her-
kömmlichen Radioimmunoassay, sowohl was Empfindlichkeit als auch die Reproduzierbarkeit betrifft. Das entspre-
chende gilt auch für die Insulin-Antikörper- und Gentamicinbestimmung. 
Die Variationskoeffizienten, sowohl innerhalb einer Meßreihe als auch von Tag zu Tag, liegen deutlich unter 10%. 
Introduction 
The use of a solid-phase covalently-coupled antigen 
opens up a new vista for immunoassays which use a 
single "tracer", namely a labelled second antibody 
(1,2). The label used in this series of experiments was 
a pyruvate kinase-IgG conjugate prepared in an ana-
logous way to a transferrin conjugate, the method 
having recently been published (3). 
The choice of a Proteohormone, therapy-induced 
antibodies and a hapten have been chosen to demon-
strate both the versatility and sensitivity of the system. 
Activated cellulose was used as the support for the anti-
gen after experiments with alternatives had led to 
unsatisfactory results. 
Not only the choice of assay buffer but also the choice 
of wash solution influenced both the sensitivity and 
unspecific binding of the assays. 
The assays here described can be seen as a further 
development of luminescent immunoassays which can 
be used routinely. 
The use of such a system brings potential problems, • 
especially in the determination of haptens, where the 
conjugate used as immunogen must be known. The 
conjugate-protein (e.g. bovine serum albumin) must 
not be used either to saturate free binding sites on the 
matrix, or as a component of the assay buffer. 
The positive effect of such an assay system is that 
potential interfering compounds (e.g. sodium azide as 
preservative) are removed from the system before the 
label comes into contact with the first antibody-
antigen complex. 
The assays are comparable with radioimmunoassays 
both in sensitivity and in precision, and are not limited 
by problems of molecular weight or quenching as are 
certain chemiluminescent assays (4). 
Materials and Methods 
Materials 
Donkey-anti-rabbit-IgG and rabbit-anti-guinea pig-IgG antisera 
were purchased from Wellcome, Burgwedel, FRG. 
Pyruvate kinase was purchased from Boehringer-Mannheim, 
Mannheim, FRG., or from Sigma, Munich, FRG. 
Microcrystalline cellulose, w-maleimidobenzoyl-N-hydroxysuc-
cinimide, adenosine diphosphate (ADP), phosphoenol pyruvate, 
bovine and porcine insulin were obtained from Sigma, Munich, 
FRG. 
Sodium metaperiodate, sodium borohydride, sodium cyano-
borohydride and all buffer reagents were purchased from 
Merck, Darmstadt, FRG. The antibodies to insulin were 
donated by Wellcome, Burgwedel, FRG. The gentamicin anti-
bodies were raised in rabbits in the hospital animal house. 
The luminometer (LKB 1250), ATP-monitoring reagent and 
accessories were donated by LKB, Düsseldorf, FRG and Wallac 
Oy, Turku, SF. 
Cellulose activation and coupling of antigens 
The activation of the cellulose with sodium metaperiodate, 
with the subsequent coupling and stabilisation of the insulin 
and gentamicin was carried out as already published for trans-
ferrin (3). 
Assay of insulin in serum 
Table 1 shows the various assay schemes for the insulin deter-
mination. Figure 1 shows the insulin assay as an example of the 
solid phase antigen luminescent technique (SPALT) here 
described. 
Assay of serum gentamicin levels 
Table 2 shows the competitive and sequential SPALT assays 
for the determination of gentamicin in serum. In the case 
of the competitive assay, the solid-phase gentamicin must first 
be titrated to ensure that the correct amount of solid-phase 
antigen is present in the system. 
Determinat ion of insulin-antibodies in human serum 
Table 3 shows the incubation scheme for this assay. As can be 
seen, one can test the specificity of the auto-antibodies by 
varying the solid-phase antigen. In this case, the solid phase 
antigen is either bovine insulin or porcine insulin. For a general 
antibody detection, a mixture of the two solid-phase antigens 
can be used. The determination of insulin antibodies follows 
the principle of the RAST-tests from Pharmacia (Uppsala, S). 
Comparat ive assays 
The assays used as comparison for the insulin and gentamicin 
determinations were radioimmunoassays, (Insulin - INSIK 3 
CIS (Isotopendienst West, Dreieich, FRG) and Gentamicin 
RIA - Diagnostic Products Corporation, (Hermann Biermann, 
Bad Nauheim, FRG.)). 
The detection of insulin antibodies was performed by allowing 
the patient serum react with radioactive insulin, followed by 
precipitation of the immunoglobulins with polyethylene glycol 
(200 g/1). 
Preparat ion of the labelled second ant ibody 
The conjugation of the immunoglobulin fraction of the second 
antibody with pyruvate kinase was carried out using the method 
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Tab. 1. The five insulin assay incubation schemes used in this study 
Assay A B C D E 
Serum/standard volume (MO 100 100 100 100 100 
Guinea pig-anti insulin (1:20000) (jul) 100 100 100 100 100 
Assay buffer (MD - - - 50 100 
Incubation time (h)/temperature (°C) 18/4 18/4 24/4 24/4 24/4 
Microcrystalline cellulose-insulin (dilution 1:100) in assay buffer (MD 100 100 100 100 100 
Incubation time (h)/temperature (°C) 6/RT+ 3/RT 8/4 24/4 24/4 
In all assays, the microcrystalline cellulose was washed twice with 1 ml wash 
at 4 °C. buffer followed by cenl trifugation at 3000 £ for 101 
Pyruvate-kinase labelled anti-guinea pig IgG - (1:100 dilution) (p\) 100 100 100 100 100 
Incubation time (h)/temperature (°C) 1.5/RT 2/RT 18/4 24/4 24/4 
The wash procedure was repeated as described above and the washed cellulose-bound pyruvate kinase labelled second antibody 
used to generate ATP from ADP and phosphoenal pyruvate in the presence of a firefly luciferase/luciferin preparation. The ATP-
production was measured kinetically in a luminometer as already described for the serum transferrin assay (1). 
RT - ambient temperature, in these experiments 18-21 °C. 
-< -< 
+ >-
X 5 
>-© 
* m>*° 
Tab. 2. Competitive and sequential SPALT assays for serum 
gentamicin assays. 
Assay Compe- Sequen-titive tial 
Standard/serum - (1:100 dilution with 100 100 
assay buffer) 
Rabbit-anti-gentamicin'(l:1000 dilution)0xl) 100 100 
Cellulose-gentamicin (1:100 dilution) (M0 20 0 
Incubation time for both assays 30 min at ambient temperature 
on a vibrator. 
Cellulose-gentamicin (1:100 dilution) (M0 0 100 
Incubation time (min) 0 30 
Both assays were subjected to the same washing procedure as in 
Table 1. 
Pyruvate kinase labelled anti-rabbit IgG 100 100 
(1:50 dilution) (Ml) 
Incubation time (min) 60 60 
Again, both assays were subjected to the same washing step as 
in table 1, followed by the same detection method for the 
ATP-production. 
All incubation steps were carried out at room temperature on 
a vibrator in order to keep the cellulose suspended. 
Fig. 1. SPALT principle 1. This shows a conventional antibody-
antigen reaction which takes place in a liquid phase. 
SPALT principle 2. The unreacted antibody is allowed to 
react with an excess of solid phase antigen. 
SPALT principle 3. After washing and centrifugation, 
the solid phase is allowed to react with the labelled second 
antibody. 
SPALT principle 4. The solid phase is then washed once 
more and then used to generate ATP, which is allowed 
to react with the luciferin-luciferase system to generate 
light (h • v). 
This is the scheme for the sequential asssy. The competi-
tive assay uses less solid phase antigen and combines the 
first two steps. 
Solid phase antigen 
^ Antigen in the sample 
First antibody 
>-© Pyruvate kinase labelled second antibody 
of Kitagawa &Aikawa (5), in which the heterobifunctional 
reagent w-maleimidobenzoyl-N-hydroxysuccinimide acted as a 
linking agent. The immunoglobulin fraction of the respective 
second antibody was prepared by precipitation with polyethyl-
ene glycol (200 g/1), followed by resuspension in 0.15 mol/1 
sodium chloride. This precipitation and resuspension was 
repeated, the resulting solution of immunoglobulins being 
coupled in an analogous way to transferrin (3) to the pyruvate 
kinase. 
Separation of the reaction mixture was performed using an 
Ultrogel A6 column (100 X 2.5 cm), fractions containing both 
pyruvate kinase and immunological activity being pooled, 
portioned and lyophilised. 
Preparat ion of the assay buffer and wash solutions 
The assay buffer used for all assays consisted of the following 
components: 
0.05 mol/1 TRIS-HC1, 2 g/1 bovine serum albumin, 0.01 mol/1 
potassium chloride adjusted to pH 7.8. 
J. Clin. Chem. Clin. Biochem. / Vol. 20, 1982 / No. 11 
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The wash solution consisted of equal volumes of assay buffer 
and 1.5 mol/1 potassium chloride. 
The buffer used in the light-generation step was identical with 
that used in the transferrin assay already published, (3), as was 
the concentration of the light-initiation mixture. 
Quantif icat ion of the immunoreact ive solid-phase 
antigen 
Dilutions of well-washed solid-phase antigen were assayed in 
the normal radioimmunoassay in the same way as serum 
samples. The removal of antibody from the reaction mixture 
by the solid-phase antigen resulted in a lower tracer binding in 
the liquid-phase. This method allows a good estimate of the 
degree of immunoreactive antigen to be made. 
Tab. 3. Insulin antibody SPALT assay scheme, showing two alter-
native methods of obtaining a "titer" measurement. 
Method 1 
100 jul cellulose-insulin (bovine or porcine) 1:100 dilution in 
assay buffer. 
100 ß\ assay buffer. 
Incubate 18 h a t 4 °C. 
Wash as in the insulin and gentamicin assays. 
100 p\ sheep-anti-human IgG-pyruvate kinase 1:100 dilution in 
assay buffer. 
Incubate 2 h at room temperature on a vibrator. 
Wash as above and measure the ATP-production as in the insulin 
and gentamicin assays. 
The results are expressed as the ratio between the signal from 
the serum to be measured to that in the negative control. 
Values over 1.50 are to be regarded as positive. 
Method 2 
The method is principally the same as above, except that the 
serum to be tested is diluted with negative control serum in 
dilution steps I part serum + 9 parts negative control serum, 
covering the range 1:10 to 1:10000. 
This allows an estimate of the antibody "titer". When the ratio, 
as described above, falls under 1.50, the serum or serum dilution 
is regarded as negative. 
The factor 1.50 encompasses a + 4 standard deviation range above 
the negative control value determined from 100 blood donors. 
Results and Discussion 
Figure 2 shows a standard curve for insulin and table 4 
the results from the different incubation schemes, the 
latter being expressed in tabular form. Figures 3 and 4 
show the gentamicin sequential and competitive assays. 
Table 5 shows correlation data between the routine 
radioimmunoassays and the corresponding SPALT 
assays for both gentamicin and insulin. 
Table 6 shows comparisons between the insulin-antibody 
assays, using sera chosen specially because of the absence 
of antibodies to both bovine and porcine insulin. Norm-
ally, insulin antibodies, when present, react with both 
porcine and bovine tracer, irrespective of the insulin 
preparation administered. 
Insulin [mli/l] 
Fig. 2. This shows a standard curve for insulin using assay E 
in table 4 as an example. The curve is plotted on semi-
log co-ordinates. 
Tab. 4. Typical standard curve data for the assays shown in 
table 1. 
Assay A B C D E 
Standard Signal in mV/min 
concentrations 
(mU/1) 
0 316 561 839 2112 2658 
334 520 872 2070 2598 
10 239 471 708 2022 2526 
251 451 793 2046 2418 
25 203 333 487 1782 2221 
198 323 468 1772 2226 
50 141 247 388 1320 1686 
141 253 362 1314 1619 
100 125 143 159 798 1134 
128 147 199 721 1116 
200 114 105 130 654 714 
109 109 132 642 678 
Unspecific binding 45 65 28 432 451 
(UB) 54 71 31 436 451 
Ratio UB: Zero 0.15 0.12 0.03 0.21 0. 
standard 
In assays A & C the cellulose was transferred to a fresh tube 
before the ATP assay was carried out. 
The assay codes are the same as in table 1. 
All values above are corrected for unspecific binding. 
Assay E was chosen as the "routine" assay, to cover the range 
10-200 mU/1. 
Table 7 shows precision data from both RIA and SPALT 
assays. 
As a result of the data in tables 5 and 7, specific recovery 
experiments were considered to be superfluous, as the 
results from both methods are seen to be the same. 
J. Clin. Chem. Clin. Biochem. / Vol. 20, 1982 / No. 11 
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Tab. 5. Correlation between the routine RIA-methods and the 
SPALT assays for both insulin and gentamicin. 
1 2 4 
Gentamicin [mg/I] 
Fig. 3. This shows a gentamicin standard curve for the sequential 
assay shown in table 2. The zero standard is set at 0.1 mg/1. 
200 
e HO 
80 
0.1 1 2 4 
Gentamicin [mg/I] 
8 16 
Relevant statistical data 
Gentamicin 
RIA 
Number 75 
of samples 
(n) 
Mean (x) 
Median 
(50th per-
centile) 
Relative 
scattering 
(C.V.)*) 
3.58 
3.24 
0.948 
SPALT 
75 
3.60 mg/1 
3.24 mg/1 
0.966 
Insulin 
RIA 
95 
13.7 
11.7 
0.633 
SPALT 
95 
13.2 mU/1 
11.4 mU/1 
0.657 
Range 
of values 0.11-12.6 0.11-13 mg/1 2.2-39.4 2.0-40.0 mU/1 
Regression analysis 
The regression equation y = a + bx was used, RIA values being 
entered as x in each case. 
Correlation 
coefficient (r) 
Intercept 
(a y x ) 
Slope (b y x ) 
Fig. 4. This shows an example of the competitive gentamicin assay 
described in table 2. The light generation is much slower 
than in figure 3 due to the lower amount of solid-phase 
antigen used. 
P-RA = Radioassay using 12SI-labelled porcine insulin as antigen. 
P-LIA = SPALT assay using solid phase porcine insulin. 
B-LIA = SPALT assay using solid phase bovine insulin. 
These patients were carefully selected for antibodies which 
were specific for only one insulin-variety. Patient 1-763 had 
antibodies which reacted with both porcine and bovine insulin. 
Most patients with insulin-antibodies react in a similar way to 
1-763 serum. 
Gentamicin 
0.998 
-0.064 
1.02 
Insulin 
0.896 
0.897 
0.898 
Standard error of the estimate y from x 
95% confidence 0.379 7.68 
limits 
99% confidence 0.569 11.5 
limits 
Lambda 0.186 4.27 
value 
The data used was normally distributed - i.e. was not signific-
antly different from a Gaussian distribution curve. 
*) The coefficient of variation was used as the measure of dis-
persion of the values used in the calculations above. 
Tab. 6. Comparison of radio- and luminescent assay data for the 
detection of insulin antibodies as described in table 3, 
method 1. 
Patient No. Age Insulin Ratio Ratio Ratio 
(a) P-RA P-LIA B-LIA 
1-370 60 Porcine 1.69 1.81 0.96 
1-390 16 Porcine 4.38 6.03 1.48 
1-441 61 Porcine 6.05 4.98 0.65 
1-469 17 Porcine 4.13 4.55 1.14 
1-475 17 Porcine 4.20 4.74 1.04 
1-493 60 Porcine 1.51 1.36 1.21 
1-580 34 Porcine 3.60 3.98 1.85 
1-592 24 Porcine 2.40 1.99 1.39 
1-601 18 Porcine 2.20 4.15 0.77 
1-695 22 Bovine 1.14 1.37 6.43 
1-763 47 Bovine 3.00 2.76 5.84 
Negative _ none 1.10 0.98 0.89 
controls - none 0.97 1.14 1.06 
- none 1.04 0.94 0.99 
Severe 72 none 0.94 2.44 3.02 
haemolytic 
anaemia 
J. Clin. Chem. Clin. Biochem. / Vol. 20, 1982 / No. 11 
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Tab. 7. Relevant statistical data comparing the performance of the RIA and SPALT assays for insulin and gentamicin in serum. 
Precision profile, shows the distribution of the coefficients of variation for the mean of duplicate values covering the range between 
the lowest and highest detectable concentrations for each assay 
Assay ns/na*) Concentration Median Percentile 
Range 2.5 16 50 84 97.5 
Gentamicin RIA 95/17 0.11-12.6 mg/1 2.30 mg/1 1.97 4.30 7.50 13.7 23.4 % 
Gentamicin SPALT 95/17 0.15-12.2 mg/1 2.50 mg/l 1.08 2.20 5.60 12.3 21.8 % 
Insulin RIA 122/13 2.20-106 mU/1 11.4 mU/1 2.00 3.30 6.30 12.5 26.1 % 
Insulin SPALT 122/13 2.70-118 mU/1 10.9 mU/1 1.98 3.71 5.40 10.3 19.7 % 
Percentiles have been used as the data were not normally distributed. The values under the percentile headings represent the precision 
in percent lying equal to or below the percentile value. For example, for the gentamicin SPALT assay 50% of all precision values lie 
under 5.6%. 
Inter- and Intra-assay coefficients of variation for two control sera lying in the lower and upper parts of the standard (dose-response) 
curve 
Assay Intra-assay Inter-assay 
RIA CV SPALT CV RIA CV SPALT CV 
n X (%) n X (%) n X (%) n X (%) 
Gentamicin 20 3.84 mg/1 3.87 20 4.10 mg/1 5.27 20 4.06 mg/l 5.80 15 4.21 mg/l 5.35 
20 10.5 mg/1 6.67 20 10.3 mg/l 4.93 20 10.7 mg/l 8.90 15 10.5 mg/l 6.75 
Insulin 20 21.4 mU/l 4.88 20 18.6 mU/1 7.26 20 25.1 mU/1 7.95 15 24.2 mU/I 9.97 
20 124 mU/1 6.41 20 136 mU/1 6.97 20 117 mU/1 9.10 15 124 mU/1 9.45 
The standards used in both methods were identical. 
*) ns/na denotes number of samples/number of assays. 
The introduction of a solid-phase antigen assay is in prin-
ciple nothing new, as this type of immobilisation of 
antigens has formed part of the in-vitro laboratory dia-
gnosis of hepatitis and specific allergies (RAST test). The 
use of an immobilised antigen and an iodinated second 
antibody as "universal label" has also been recently 
published for haptens in a competitive assay (1,2). The 
novelty of the SPALT is its capability to measure both 
proteins and haptens without radioactivity, and with 
a sensitivity equal to that obtainable in radioimmuno-
assay. The sensitivity of the SPALT insulin assay, defined 
as the lowest detectable concentration or the value read 
off the standard curve using a count-rate 2 standard 
deviations lower than the mean zero standard count-
rate, is under 5 fmol per tube (equivalent to < 3 mU/1) 
for the routine assay using a 100 /il serum sample. 
The use of a sequential assay technique has all the 
advantages of the immunoradiometric type of assay 
inasmuch as an excess of solid-phase antigen can be used, 
as well as an excess of labelled second antibody. The 
precision of the assay depends to a large extent upon 
the first step of the assay, i.e. the pipetting of sample 
and first antibody. The form of the standard curve is 
similar to that of a conventional radioimmunoassay, 
i.e. maximal signal at minimal analyte concentration, 
so that the signal at this concentration corresponds to 
an almost 100% "bound tracer signal". 
The use of a second antibody label, apart from its 
universal application to all assays using a common-
species first antibody, means that the reagents used in 
the first reaction step may contain preservatives norm-
ally found in radioimmunoassay systems, e.g. sodium 
azide, as these are removed from the system during the 
first wash step, i.e. before addition of the pyruvate 
kinase labelled second antibody. Problems can arise 
when a choice of preservative for the second antibody 
solution has to be made. Addition of antibiotics to 
the reconstituted label appear to have no deleterious 
effects, bearing in mind that the choice of antibiotic 
may be critical, as in the gentamicin assay for example. 
The insulin assay here described shows that the optimal 
signal to blank ratios are obtained with assay E, that is, 
an assay with a three day incubation, although accept-
able sensitivity and precision can be obtained using 
shorter assay times. The optimal design lies in the 
choice of both first and second antibodies, and also upon 
whether the antibodies are purified before use, (1). The 
general opinion now appears to favour the use of mono-
clonal second antibody for labelling, not only because of 
specificity, but also because of the purity of the reagent 
which can be obtained {Voller, A. & Hunter, W. M.9 
personal communications). 
The gentamicin assay can either be performed as a 
sequential or competitive assay, the latter resulting 
in a quicker assay, but lower signal as the solid-phase 
antigen must be present at much lower concentrations. 
The use of excess reagents allows for a greater margin 
of error in pipetting and is reflected in the precision 
obtained for the assays here described. Using a specific 
solid-phase insulin allowed the detection of mono-
specific antibodies to either porcine or bovine insulin 
in a small number of patients, although, as stated 
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above, most patients had antibodies which bound both. 
An important criticism of the SPALT assay as described 
here, is the need for thorough washing of the solid-phase 
between steps. Before such an assay can have a chance, 
commercially speaking, a solid-phase must be developed 
which is easy to handle, and if possible, easy to wash 
without having to use a centrifuge-step. Preliminary 
results show that in the case of larger antigens such as 
thyroxine binding globulin (TBG), treated glass balls 
can replace microcrystalline cellulose as a support to 
which the TBG is covalently coupled. Whether a similar 
technique can be used for haptens is still to be seen, 
although the results of Stafford and Kilgallon (1 ,2) show 
that it should be possible. 
Superficial studies show that there is nothing to stop 
other labelled second antibody preparations being used 
in a solid phase antigen technique. Replacement of 
pyruvate kinase by azoluminol leads to a SPALT 
assay using a chemiluminescent detection system (6). 
This type of assay has also been used to measure genta-
micin using an identical assay system as here described. 
Peroxidase labelled second antibody has been used to 
detect the presence of gonococcal antibodies using a 
gonococcus extract covalently attached to micro-
crystalline cellulose (Wood, unpublished data). Although 
bilirubin in concentrations up to five times the upper 
limit of the normal range have had no effect on the 
results, the possibility exists that haemolytic serum may 
contain sufficient pyruvate kinase to affect the results. 
To remove such effects, pyruvate kinase inhibitors can be 
added to the first incubation step, provided that the con-
centrations used allow a complete removal from the 
system before the second antibody incubation step. 
Lipaemic sera affect the SPALT in the same way as a 
normal radioimmunoassay inasmuch as the large 
amounts of fats inhibit the antibody-antigen reactions, 
as well as swamping the solid-phase antigen. 
In the search for a more acceptable solid-phase for 
haptens, it cannot be excluded at this stage that an alter-
native to pyruvate kinase may have to be found, as it 
appears that the second antibody-pyruvate kinase 
may be sterically hindered from binding to the first 
antibody-antigen complex when using a high-density 
solid-phase such as glass or activated Teflon. An attrac-
tive alternative, at least on paper, is adenylate kinase 
(EC 2.7.4.3) because of its low molecular weight 
(21000) and stability against heat and pH-changes. 
As with all new techniques, the impact of the luminesc-
ence immunoassays as described here depend upon the 
availability of automated luminometers, as well as 
robust commercial kits. 
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